 Lipocine Inc NASDAQ: LPCN has announced topline 36-week results from its Phase 2 proof of concept LiFT study investigating LPCN 1144 in Non-Alcoholic Steatohepatitis NASH. LPCN 1144 comprises an orally delivered prodrug of endogenous testosterone T. 